MC
TEVA icon

Muhlenkamp & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Muhlenkamp & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-700
Closed -$13K – 62
2017
Q4 		$13K Hold
700
– – ﹤0.01% 73
2017
Q3 		$12K Sell
700
-105,805
-99% -$2.38M ﹤0.01% 75
2017
Q2 		$3.54M Sell
106,505
-140
-0.1% -$4.33K 1.11% 29
2017
Q1 		$3.42M Sell
106,645
-133,244
-56% -$4.55M 1.05% 30
2016
Q4 		$8.7M Buy
239,889
+64,119
+36% +$2.56M 2.75% 16
2016
Q3 		$8.09M Sell
175,770
-885
-0.5% -$46.2K 3.05% 14
2016
Q2 		$8.87M Sell
176,655
-505
-0.3% -$26.9K 3.47% 10
2016
Q1 		$9.48M Buy
177,160
+205
+0.1% +$12K 3.87% 8
2015
Q4 		$11.6M Hold
176,955
– – 3.49% 13
2015
Q3 		$9.99M Buy
176,955
+40
+0% +$2.59K 2.93% 16
2015
Q2 		$10.5M Buy
176,915
+205
+0.1% +$12.6K 2.26% 22
2015
Q1 		$11M Buy
176,710
+325
+0.2% +$18.9K 2.32% 22
2014
Q4 		$10.1M Sell
176,385
-470
-0.3% -$26.2K 2.03% 23
2014
Q3 		$9.51M Hold
176,855
– – 1.72% 27
2014
Q2 		$9.27M Buy
176,855
+1,415
+0.8% +$72.3K 1.64% 29
2014
Q1 		$9.27M Sell
175,440
-900
-0.5% -$41.6K 1.63% 27
2013
Q4 		$7.07M Buy
176,340
+6,355
+4% +$250K 1.23% 29
2013
Q3 		$6.42M Buy
169,985
+325
+0.2% +$12.7K 1.28% 29
2013
Q2 		$6.65M Buy
+169,660
New +$6.61M 1.39% 28

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Muhlenkamp & Co's TEVA Position: Q1 2018 in Review

Muhlenkamp & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 700 shares — an estimated $13K sold.

Muhlenkamp & Co first reported a position in TEVA in Q2 2013 and held it in 19 quarters. The position peaked at $11.6M in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Muhlenkamp & Co reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Muhlenkamp & Co sold 700 Teva Pharmaceuticals shares in Q1 2018, an estimated $13K.
  • Muhlenkamp & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Muhlenkamp & Co's Teva Pharmaceuticals position peaked at $11.6M in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Muhlenkamp & Co's 13F filing for Q1 2018, filed 11 May 2018.